OpGen closes $7.5M public offering of common stock and warrants

CapForce Inc.

Sold 2,586,207 shares/common or pre-funded warrants, plus Series A-1 and A-2 warrants at $2.90 per combined unit.
Gross proceeds approximately $7.5M; net proceeds to fund commercialization of Acuitas AMR Gene Panel and Unyvero Platform.
Proceeds also allocated to Ares Genetics development, sales/marketing, manufacturing infrastructure, and debt repayment.
H.C. Wainwright acted as exclusive placement agent, receiving 6.0% cash fee.
Offering closed on January 11, 2023 under effective S-1 registration statement (File No. 333-268648).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CapForce Inc. entered into Purchase Agreement with a certain institutional investor valued at aggregate gross proceeds of approximately $7.50 million (effective 2023-01-06).

Action: entry
Agreement: equity purchase
Counterparty: a certain institutional investor
Value: aggregate gross proceeds of approximately $7.50 million
Effective: 2023-01-06

Exact text from the filing

On January 6, 2023, OpGen, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”)

View on SEC.gov

Browse all material agreements →

CapForce Inc. filing history →

Source: SEC EDGAR

accession 0001079973-23-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.